*amada* Gratulation Kauf 0,06 TOP 0,32 und nun rein in CALY 909402 - 500 Beiträge pro Seite

[DieNEUE]

amada ALLEN ERNSTES nach 433 % Gewinn in 3 Tagen sollte man eine neue Chance suchen.
CALY kommt von 7,5 USD und ist nun bei 0,26 USD
Market Cap (Mil) $ : 6.70

Calypte macht den einzigen HIV-Test (AIDS) auf URIN-Basis statt mit BLUT
WELTWEIT ist CALY die einzige Firma die eine Zulassung dafür hat.
WKN 909402
Ticker in der USA *CALY*
Ich habe gekauft.

Das ist die nächste Chance 433% zu machen.
MfG
DN

[Schimpo]

Man, Man, Man. Amada hat sich innerhalb von einem durchnittlichem W.O. Bord Teilnehmer zum Superguru verwandelt. Herzlichen Glückwunsch dazu, aber was ich dadran so armsellig finde, ist das jetzt so ungefähr jeder Trittbrettfahrer sie als Aushängeschild nehmen will.
Wo ist ein Nagel, damit ich ihn mir in meine Hirnwindungen schlagen kann.
Leute, versucht nicht irgendjemanden dazu zu mobilisieren eure Furzaktien in den Mittelpunkt zu stellen, da sie sonst nichts reißen.
Auch Amada kann keine fundamentalen Daten ändern, egal wie sie es darstellt. Also lass Dir das auf der Zunge zergehen, und schieb Dir nen Gullideckel quer in Deine Harnröhre.

In diesem Sinne, locker bleiben


Schimpo

[Schimpo]

Ich meinte natürlich, nicht Harnröhre sondern vielmer wulstige Lippen. Haha

[DieNEUE]

1. Übernahmephantasie denn CALY macht den einzigen Urintest in der Welt, der FDA- Zulassung besitzt, mit FDA-zugelassener Produktionstätte, mit einem Abnehmer wie China!
2.Das beste Quartal der Firmengeschichte in Bezug auf den Umsatz
3. Der BIO-HYPE ist im Anmarsch
MfG
DN

[DieNEUE]

Geht los da drüben.
Last Change (%) Bid (size) Ask (size) Trade Time
0.25 0.01 (4.17) 0.24 (100) 0.25 (134) 11:28

Aufspringen und ab zur 4$ Party
DN

[Krumbein]

Nee, nee. EINEN AMI-Pennystock hier lasse ich mir ja noch gefallen, aber damit ist es dann auch gut. Wenn Ihr Eure Ami-Zocks diskutieren wollt, macht das doch bitte im passenden Board.

Bitte verschieben. Wir haben ja alle gesehen, was passiert, wenn das einreißt. Nach drei Wochen traut sich keiner mehr, die Guru-Boards zu verschieben.

[amada]

Andi Spazy hör auf Deinen Schrott mit meinem Namen zu pushen !!!!

Ich kenne die Firma nicht und rate daher jedem von einem Kauf DRINGEND ab - was Andy Spazy=Die Neue hier macht ist Trittbrettfahren um Schrott zu pushen.

Gruß Amada

[DieNEUE]

Sehe Dir mal die Story an
Die gibt es nicht in GERMANY
Keine Morphosys hat diese Story

CALY ist der Renner in den nächsten Wochen.
Weißt Du was es kostet die FDA ZULASSUNG ?
Die Kosten für so etwas waren immens hoch, abgesehen von der Zeit die benötigt wurde um von der Food and Drug Administration (FDA) eine Zulassung für den Test und der Produktionsanlage zu erhalten.
CALY wird mit Sicherheit übernommen oder bekommt eine fette Finanzspritze aber man kann CALY nicht fallen lassen.

Afrik und China benötigen den Test

Nur bei dem Chaos an den Märkten bemerkt das keiner.
Deshalb mach ich mal etwas Aufmerksamkeit für eine kleine Perle.
Die Story könnte ja doch mal einer mit etwas Geld in der Tasche interessant finden.
Ein Risiko einen Teil der Gewinne von ENNT mitzunehmen und in CALY zu stecken sehe ich nicht, außer einer zweiten großen Chance
MfG
DN

[amada]

Trotzdem Schrott - da Du es nötig hast mit ENNT und meinem Namen zu pushen kann die Aktie nur Schrott sein

Die würde ich nicht mit der Beißzange anfassen - die hast Du genauso kaputtgepusht wie Spaz

Gruß Amada

[Megapol]

@DieNEUE

Der Unterschied zu amada ist, daß dieser mit Fundamentaldaten aufwarten konnte und so die User von der "Qualität" (ich würde dieses Wort nicht unbedingt auf die empfohlene Aktie beziehen) seines Wertes überzeugen konnte. Ansonsten würde er wie Du oder die User, die gestern Lycos bzw. Travelshop empfohlen hatten, als reine Pusher abgestempelt werden und hätte nicht den Erfolg erzielt.

Gruß
Mgp

[edwinmoses]

Habe die Aktie schon seit längerem auf meiner Watchlist. Werde wohl auch bald einsteigen.Zahlen waren nämlich sehr gut! Denke auch an eine Übernahme!!!

[DieNEUE]

O.K.
Fakten
Quelle:
http://www.marketguide.com/mgi/SNAP.asp?nss=www&rt=snap&rn=A…

Calypte Biomedical Corp.
1265 Harbor Bay Parkway
Alameda, CA 94502
Phone: [phone]
Fax: [phone]

Employees: 65 (12/31/2000)

Market Cap (Mil) $ : 6.70

Umsätze der letzten Jahre
REVENUE
Quarters 1998 1999 2000 2001
MAR 241 -834 -1,098 -1,402*
JUN 296- 914- 787
SEP 147 -1,077 -835
DEC 267 -903- 576

Totals 951- 3,728 -3,296 -1,402*
Note: Units in Thousands of U.S. Dollars

Siehst Du die Steigerung ! NUR in diesem Quartal haben wir schon 1,4 MIO Das hatten wir nicht im gesamten Jahr 1998 und der Kurs war 1998 bei 7,5 $

Der Kurs ist im Augenblick bei 0,26 $

Das 10 fache also 2,6 $ wäre mehr als fair.
MfG
DN

[amada]

Schrott - und mehr sage ich dazu nicht mehr

Gruß Amada

[times.]

kann mir jemand den pendant zu e-net in den usa nennen. kann die vergelichsaktie nicht finden.

danke

[DieNEUE]

amada NEIN kein Schrott
Sehe die letzten Berichte
--------------------------
Calypte Biomedical Corp. Sells Minority Stake in Pepgen April 23, 2001
Calypte Biomedical Corp. announced that it has sold its 29% minority position in Pepgen Corporation, a privately held therapeutic company, for $500,000. Calypte`s decision to sell its Pepgen stake reflects the company`s commitment to its core diagnostics business and provides immediate access to cash needed to pay down debt and finance expenditures.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. Announces First Quarter Revenues and Status April 12, 2001
Calypte Biomedical Corp. announced that its preliminary first quarter revenues for the three months ended March 31, 2001 had exceeded its previous best quarter. At the same time, the Company stated that it does not believe that its currently-available financing will be adequate to sustain operations at current levels through the second quarter of 2001. In addition, the Company is currently in discussions with the staff of Nasdaq regarding the Company`s failure to meet the net tangible asset requirement for continued listing on the Nasdaq SmallCap Market set forth in the Nasdaq Marketplace Rules.

[Skiniwilli]

Das wäre e-loan (EELN). Die sind höher bewertet, haben aber auch mehr Umsatz.
Und: Sie haben eine frische Finanzspritze erhalten, also Kohle. Genau das fehlt e-net, die ja auch selbst zugegeben hatten, dass ihre existenz als going-concern gefährdet sein könnte.

[DieNEUE]

Die Zahl der Aids-Infizierten wird in Südafrika im kommenden Jahrzehnt voraussichtlich von derzeit mehr als vier auf sieben Millionen steigen. -PUNKT-
Eure NEUE

[Forum]

Calypte Biomedical Notified of Potential Nasdaq Delisting


ALAMEDA, Calif., May 16, 2001 (BUSINESS WIRE) -- Calypte Biomedical Corporation
(Nasdaq: CALY) today announced that it was notified by Nasdaq that the Nasdaq
staff had reached a determination to delist Calypte`s common stock from the
Nasdaq SmallCap Market. Nasdaq`s decision to delist Calypte`s common stock was
based on Nasdaq Marketplace Rule 4310(c)(2)(B) and results from Calypte`s
failure to meet the three criteria relating to net assets, market capitalization
or net income.

Calypte has requested an oral hearing to review Nasdaq`s determination. The
hearing request stays the delisting of Calypte`s common stock, which otherwise
would have occurred on May 21, 2001, pending the decision of a Nasdaq Listing
Qualifications Panel. There can be no assurance that the decision of the Nasdaq
Listing Qualifications Panel will be favorable to Calypte. If Calypte`s common
stock is delisted following the hearing, the Company`s shares would likely trade
over the counter. Additionally, the Company`s continued ability to use its
equity line of financing facility is dependent upon its continued listing on the
Nasdaq SmallCap Market and any outstanding balance on its 6% convertible
debenture would become due and payable should the delisting occur.

Calypte`s President, CEO and CFO, Nancy Katz, stated, "We previously announced
this possible action by Nasdaq a month ago, and this determination letter from
the Nasdaq staff is one more step in the delisting process. While there can be
no assurance that the Listing Qualifications Panel will grant the company`s
request for continued listing on the Nasdaq National Market, we will continue to
pursue all available means to maintain this listing in concert with our active
search for strategic opportunities including investment in the Company, a merger
or other comparable transaction, the sale of certain of our assets or a
financial restructuring to sustain our operations. While some of these
opportunities are promising, we do not have any agreements in place."

Calypte Biomedical Corporation (Nasdaq: CALY) headquartered in Alameda,
California, is a public healthcare company dedicated to the development and
commercialization of urine-based diagnostic products and services for Human
Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other
infectious diseases. Calypte`s tests include the screening EIA and supplemental
Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be
used on urine samples. The company believes that accurate, non-invasive
urine-based testing methods for HIV and other infectious diseases may make
important contributions to public health by helping to foster an environment in
which testing may be done safely, economically, and painlessly. Calypte sells
its products in over 40 countries worldwide through international distributors
and strategic partners.

Statements in this press release that are not historical facts are
forward-looking statements, including statements regarding the outcome of a
Nasdaq hearing on delisting. Such statements reflect management`s current views,
are based on certain assumptions and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to our ability
to obtain additional financing that will allow us to continue our current and
future operations, our ability to draw down funds under our existing equity line
of credit and debenture agreements and whether demand for our product in
domestic and international markets will continue to expand. The Company
undertakes no obligation to publicly update these forward-looking statements to
reflect events or circumstances that occur after the date hereof or to reflect
any change in the company`s expectations with regard to these forward-looking
statements or the occurrence of unanticipated events. Factors that may impact
the Company`s success are more fully disclosed in the Company`s most recent
public filings with the U.S. Securities and Exchange Commission, including the
periodic report on Form 10-K for the year ended December 31, 2000 and its Form
10-Q for the quarter ended March 31, 2001.


CONTACT: Calypte Biomedical Corporation, Alameda
Nancy Katz, 510/749-5100
President, CEO and CFO

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2001 Business Wire. All rights reserved.

[Destroyers]

@all
glaubt Ihr ernsthaft der Hype bei ENNT hat auch nur im Entferntesten mit der "Board-Nase" amada zu tun
Ich glaub der/die überschätzt sich gewaltig.
In 2 Wochen redet keine Sau mehr von der/die. Da gibt es eine Menge anderer User, die das Prädikat "Wissender" verdient haben. Ich könnte mich über das substanzlose Gesülze totlachen.
Nach dem Kleinanleger-Motto: "Ich will auch mal dabei sein"

In go(l)d we trust
Destryer

[Megapol]

In 2 Wochen redet keine Sau mehr von der/die.

@Destroyers

Glaub ich nicht. Sollte der Zock nach hinten los gehen, würden einige im Board ziemlich ungemütlich werden und die ID amada wohl der Geschichte angehören

[DieNEUE]

@Forum
Diesen Brief hat der Markt bereits verdaut und fast jede Firma an der Nasdaq unter 1 USD hat diese Androhung bekommen.
Übriegens war es auch der Grund des Abschmierens.
Ich sehe es aber sogar als eine Chance.
Stell Dir vor die gehen wieder über 1$ (durch eine besondere Nachricht ) und dann kommt die News CALY bleibt an der Nasdaq gelistet.
mfG
DN

[DieNEUE]

Fakten:
- An der Immunschwächekrankheit sterben jährlich 2,8 Millionen Menschen.-PUNKT-

der Kurs steigt aktuell um 8% -PUNKT-
DN

[frohgemut]

@DieNEUE
Vielleicht sterben nicht 2,8 sondern 28 Millionen !
Dann haben wir nicht 50% sondern 500 !

[DieNEUE]

Eigentlich ein scheiß Thema
Ich hoffe mit meiner Investition diesen Menschen zu helfen.
Dann bin ich nicht nur ein Zocker sonder mache auch eine humanitäre Hilfe.
Stabilität im Aktienkurs sollte auch die Weiterführung der Tests helfen.
MfG
DN

P.S.
Gleich schneidet der MACD im daytrader Chart von unten nach oben.
Die 0,30 USD könnten wir heute noch sehen.

[DieNEUE]

- Mehr als 70 Prozent der weltweit mit dem AIDS-Virus infizierten Menschen leben auf dem schwarzen Kontinent.
und hierzu eine News vom Dezember 2000 von Calypte
-Dec 1, 2000—On World AIDS Day,Calypte tests used in new testing and treatment strategy in South Africa -PUNKT-
MfG
DN

[DieNEUE]

Nun habe ich aber etwas gefunden
Quelle:http://www.rethinkingaids.de/afrika/freivon.htm

-Ebenfalls im Dezember gab die Weltbank zusammen mit dem IWF und einigen Gläubigerstaaten einen Schuldenerlaß bekannt: Für 22 Länder, unter ihnen viele in Afrika, stehen 42 Milliarden US-$ zur Verfügung, weitere 28 Milliarden US-$ sollen entsprechend vergeben werden. -PUNKT-

MfG
DN

[DieNEUE]

UND nun die WAHRHEIT
Der Chart



Ihr seht dass der MA9 -gelb-den MA18 schneidet (MA-heißt Moving Average auf Deutsch gleitender Durchschnitt)

Das ist in der Charttechnik ein klares Kaufzeichen.
Die Überhitzung von 70% Tagesgewinn vor 4 Tagen wurde abgebaut und nun kann in Ruhe und mit guter Überlegung gekauft werden.
Die ganze Hektik bringt nichts außer verärgerte Anleger.

Nun kann jeder überlegen ob CALY ein Kauf ist oder ob man es nur aus der Ferne beobachten sollte.
MfG
DN

[DieNEUE]

Ich war mal suchen für Euch.
http://aids-info.net/micha/hiv/aids/ain_index.htm

Alles zum Thema AIDS
MfG
DN

[DieNEUE]

32% plus
Nachbörslich auf 0,38$ das sind 0,44 Euro
Fein und nun folgen drei weiße Kerzen.
Ich vermute bis 1$
MfG
DN

[Diagonale]

andy!

Nicht überheblich werden! Du hattest heute einen guten Tag.
Bescheidenheit ziert sich.

Gute Nacht
Diagonale

[DieNEUE]

Ich bin bescheiden.
1 USD und die NASDAQ bleibt uns treu
MfG
DN

[DieNEUE]

Seit meiner Empfehlung geht CALY nur hoch.
Wer von Euch hat auf mich gehört ?
MfG
DN
Übriegens über 1$ gibt es auch kein delisting mehr dann kommt ein zusätzlicher Anstieg bis 4$

[DieNEUE]

Wisst Ihr was Calypte heißt ?
Kolibri


Und deshalb fliegt der Kurs bis 1,35$ noch in dieser Woche.

[TheAdvisorNo1]

Ich sage, vollkommen lächerlich. ENNT ist etwas vollkommen anderes. Ein wirklich interessanter Zock ist der von Finance Coach im OTC-Forum,

- Eye Dynamics, Inc. (Bulletin Board - EYDY)

Die haben den weltweit schnellsten Drogentest (FDA approved) entwickelt, der auch noch einer der kostengünstigsten ist.

Finance Coach will 1000% in 2 Monaten machen. Ich halte das für realistisch und werde einsteigen. Die Aktie notiert 0.31 Kursziel von Finance Coach 3$ in 2 Monaten.

Firmeninfo unter www.eyedynamics.com

Artikel im Spiegel haben die auch schon

[Sackbauer1]

hab auch heute mein depot von ennt halbiert und eine hälfte in caly investiert. eine der beiden wird hoffe ich schon ein reisser sein.

[TheAdvisorNo1]

Ich sage euch, ein wirklich guter Zock ist Eye Dynamics, stellt euch das mal vor, die haben einen Drogentest, der dauert nur 30 Sek.

DAS IST DER HAMMER!!!

In Albama nutzen die Behörden diesen Test schon!! Die Aktie wird abgehen, da noch in den nächsten Wochen Riesenaufträge warten.

[TheAdvisorNo1]

0.310 +0.050 +19.231

ES GEHT LOS!!!

EYE DYNAMICS, INC. (OTCBB:EYDY)
Shares (Millions) 11.900
Market Cap (Millions) 3.090


2301 W. 205th St., #106 Torrance, CA 90501, USA
Phone: [phone]

www.eyedynamics.com

email: [e-mail]

[Boersenkraehe]

Wie lautet die WKN ?

Danke

[TheAdvisorNo1]

WKN 883610 Eye Dynamics, Inc. (OTCBB:EYDY)

ENNT: US$0.18 in des USA. Wieder aufwärts??? Immerhin hat jemand 15,000 shares zu 0.17 gekauft!

[Viva-los-Tioz]

EYE DYNAMICS INC - OTC BB: EYDY

Last Change (%) Bid (size) Ask (size) Trade Time
0.31 0.05 (19.23) 0.26 (50) 0.31 (50) 09:31
Day Volume Last Size Open High Low
700 700 0.31 0.31 0.31
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 1 700 N/A N/A
Prev Close VWAP Avg Day Vol
0.26 0.31 N/A
1:53:56 PM EDT - Monday, June 11, 2001 - data is real-time.

[TheAdvisorNo1]

THE INSIDER REPORT
Buy Recommendation: Eye Dynamics, Inc (NASD-OTC:EYDY)
Strong Buy Rating (Speculative) 35c

BACKGROUND
You`re at MSY in New Orleans when you hear your boarding call ring over the airport PA. The fatigue from last night`s Mardi Gras party rips at your thighs and your head is being pounded heavily by the remnants of last nights "Rum Delights" as you start moving towards your gate. As you approach the gate, you notice the pilot and his crew boarding and you think to yourself, "I sure am glad they were getting their sleep last night and not out `till four like I was...". Or were they?
This scenario may seem innocent enough but just how secure would you feel had you known prior to boarding, that your pilot was the guy sitting three barstools down at that raging party last night? He may have not even touched an intoxicating drink, but did you know that sleep depravation is an even more powerful and common culprit in the causing of accidents and poor or dangerous work performances? Mix in any kind of drug abuse - prescription or otherwise - and you have some frightening and deadly combinations.
What`s even more scary is that more times than not, there is no way to verify the symptoms of these abuses that can put literally hundreds of lives in danger in many situations. How could you verify on the spot that the pilot who is about to take 200 or more lives 10,000 feet into the sky only had 2 hours of sleep last night and took 2 percodans to kill the headache his lack of sleep caused? Or what about that truck driver who is about to take 2000 gallons of highly explosive and volatile chemicals on a150 mile trip on our public highways right after finishing another 2-day, sleepless drive for another contractor? The list goes on and includes fork lift operators, surgeons, bus drivers, cops, mom`s taking the kids to school and many, many others.
Now there is a way for an employer or any other type of authority to instantly inspect the condition of any employee quickly, cost efficiently and most importantly - accurately! This patented and well tested technology could prove to be not only revolutionary to its industry but, critical in preventing accidents, cutting liability costs for businesses of all types and sizes and best of all - savings hundreds of lives! Eye Dynamics Inc. (OTCBB, EYDY) has developed this product and calls it SafetyScope. What is even more exciting is that EYDY is evolving this product into a revenue model that would secure profits off each placement of the system long into the future, rather than being a "one time" revenue producer.
As exciting as SafetyScope is, it is not the only product EYDY has developed and patented. The House InfraRed/Video ENG System is another invention of this micro-cap gem and, as you read more about these two fascinating technological achievements, you will see why Eye Dynamics is worthy of a position in your micro-cap portfolio. The combination of proprietary technology along with computer software in order to produce a product that even the US government says performs with an accuracy that is second to none, makes EYDY one of the most intriguing micro-cap stories we have come across in a long time.
BUY RECOMMENDATION
The emphasis of consideration for investing in EYDY is based on several important factors:
The fact that the company has developed a recurring revenue model evolving around the SafetyScope product, creates the opportunity for substantial revenue growth immediately and well into the future. Fees will be administered "per test" and systems will be provided at no cost. This revenue model benefits not only EYDY, but also the company`s clients by cutting down on upfront expenditures. As long as the product remains a leader amongst these technologies the demand for the accurate, time-efficient level of results it produces will continue to expand. Current methods of urine testing are highly subjective to human errors such as contamination, mix-ups and other inefficiencies. Urine testing methods are also time consuming - it takes time to administer the test or obtain the sample, then it takes even more time to obtain the results, whereas a test administered by SafetyScope returns a result immediately. By providing an alternative to the potential mishandling and slow time frames of traditional urine testing SafetyScope provides an important service to society on both a safety and business level.
Additionally, the technology used in SafetyScope is proven and documented. The system has repeatedly outperformed all competitors and provides a much-needed alternative to an old and inefficient method of testing. The company has dedicated over ten years of research and development into this system, based on the company`s FDA-approved and patented medical technology.
As mentioned previously, there are a number of efficiencies provided by SafetyScope that make urine testing an outdated and inconvenient method in comparison. Currently urine-based drug testing generates over $1billion a year in revenues. By providing an alternative that is easier to use, cheaper to use and produces results faster, it is prudent to believe that a large portion of that market will be obtained by SafetyScope.
The expertise and longevity of management as a team solidifies EYDY as an exciting investment opportunity. The team has been together for over 12 years and includes a group that has experience in vital areas of business and medicine - Chairman Ron Waldorf is a renowned expert in vesticular physiology. Their expertise in eye physiology, medical product development and other core business skills adds a legitimacy not often found within the micro-cap arena.
To summarize the major points of this investment:
· Maximizing of revenue growth potential - A viable and recurring revenue model which ensures revenue growth for an extended period of time, rather than being susceptible to the moods of sales cycles and economic conditions.
· A vital technological edge over the competition - Proprietary technology that is cutting edge within the medical equipment industry. 12 years of R&D along with previous FDA approvals. A proven technology which helps fill a void to a vital social dilemma. A second product technology in which the company achieved the first major technological breakthrough in 40 years (VNG)
· Important player in a large, established market - A more efficient and convenient product ready to enter an already $1B/year marketplace and replace an old, inefficient technology.
· Skilled management with established track records of success - Management with experience in the medical industry AND in building successful businesses. A team that has been together for over 12 years.
COMPANY PROFILE
Back in 1988 two men, Ronald Waldorf and Charles Phillips, joined forces to form OculoKinetics, Inc. The goal of this merger was to combine their business and scientific backgrounds to create commercial applications of Waldorf`s expertise in vestibular physiology. In 1991 a company called Petro Plex acquired OculoKinetics in a reverse merger with OculoKinetics management taking the key positions. After changing the name to Drug Detection Systems the company finally became Eye Dynamics in 1993. The encouraging part is that Waldorf and Phillips still hold the positions of Chairman and President, respectively, and the company has two patented products which have achieved high standards of success and are leaders in their respective technologies.
Based in Torrance, CA, Eye Dynamics is engaged in the design, development, manufacture and distribution of equipment and related systems, which measure and record human eye movements in response to certain stimuli. Because the eye is such a sensitive organ, eye movements are reliable indicators of the presence of diseases, drugs, or other conditions which can adversely affect the human visual-motor systems. Eye Dynamics focuses on the central nervous system condition of nystagmus - a rapid, involuntary oscillation of the eyeball. This condition occurs in a variety of forms with a number of causes ranging from the serious (tumor of the brain or ear) to the benign (curable dizziness). Consumption of alcohol and/or drugs are also a cause of nystagmus - there is even a correlation between the degree of nystagmus and the amount of alcohol consumed. The company has developed two products which are cutting edge and revolutionary. Because of the magnitude of these achievements EYDY could be the success story of the year - and for years to come.
PRODUCTS
SafetyScope
Ask yourself this: How important would a product that could identify an impaired worker within 90 seconds be to a company that has workers involved in potentially perilous situations, or even involved in situations in which public safety is at risk? The amount of money that could be saved on insurance, workman`s comp. and other liability costs would be enormous. Not only that, people`s confidence in your company`s ability to provide a safe service -such as pilots, bus drivers, etc. - would provide a nice boost to any business. This idea isn`t as far fetched as it sounds, in fact, it`s a reality.
Time savings is the most obvious benefit of SafetyScope. Within a ninety second time-frame the technology measures 20 parameters of eye movement and pupil change. It then reports back a "Pass" or "Fail" result with incredible accuracy. The system works off a simple and safe user-friendly operation making it viable solution for any safety conscious environment. Simply put, the system is fast, economical and simple to use, positioning EYDY to be a major player within the Performance testing arena.
There are tremendous issues at question with urine testing, with the invasive nature of the latter being one of the most common. This presents another benefit of SafetyScope over UA`s, or even breath and hair sample testing. The SafetyScope simply peers into the test subject`s eye and returns a result of "Pass" or "Fail" without having intruding any deeper into a person`s lifestyle other than the fact are they impaired or not. It also presents a non-demeaning method for obtaining the results - no more "pee-while-they-watch" testing - and it`s also much more sanitary for both party`s involved.
Two factors that may come into play as critical to the success of this system are its ability to produce instant results and the fact that it is impossible to "fake" eye movements. Although not documented, urine analysis results can supposedly be altered through the intake of chemicals formulas which are sold over the counter and are totally legal. By taking these formulas the testee could return a "clean" or negative result when in fact, the result was just the opposite. There is no fooling the SafetyScope since eye movements, pupil constrictions and dilation are involuntary.
The second factor mentioned puts SafetyScope head and shoulders above any competition. If it takes 3-7 days to obtain the results of a urine test then there is the potential that someone is performing their duties WHILE under the influence of suffering from sleep depravation. By the time the results come back it could be too late. SafetyScope eliminates any chance of this ever happening by providing a result in real-time, right on the spot!
The revenue model being designed for SafetyScope puts an emphasis on optimal returns while providing the most economical way for any company to put the system to use. EYDY will place the system on a company premises and a royalty of $3 per test. Doesn`t seem like much at first but when you consider the unit has an assumed lifespan of 3-years, the company estimates that a system which costs $7,000 to manufacture will generate over $97,000 in revenues during that lifetime.
The House InfraRed/Video ENG System
It`s always encouraging for an investor to know that the company they are involved with has played a role in the development of a technology that separates them from the could-have-beens and the wannabees. This system is one of those products and something that has established EYDY as an important player in their industry.
The simplest way to explain The House InfraRed/Video ENG System is to start in the middle - ENG! Electronystagmographic (ENG) testing was originally performed by adhering electrodes to a patient`s skin to allow for data acquisition. The purpose of the test is to detect the condition of nystagmus - "a rapid, involuntary oscillation of the eyeball" (thanks Mr. Webster!). There are different levels of nystagmus and the causes can range from serious (brain or ear tumors) to benign (positional dizziness). Fairly simple right? Yes, but not so comfortable nor convenient for the patient or physician.
So in 1994 Eye Dynamics took ENG testing to a new level by gaining FDA approval of the House InfraRed/Video ENG System. This revolutionized ENG testing by replacing the old method of adhering electrodes to the patient with a lightweight, comfortable and durable goggle assembly. The patient just looks into the goggles and Ocular Motor Module (OMM) and all the tests are performed instantly. The old ENG is effectively replaced by the new technology, VNG Videonystagmography!
The system runs on a streamlined and simple software program that is the fastest test station available in the industry. It uses its proprietary Eye Position Interface Controller (EPIC) boards to "lock" onto the pupils and independently track the horizontal and vertical movements of each eye. The nystagmus is displayed in real time, saved, analyzed and printed. The four channel system comes with a 12" Quad/Video Monitor that displays both eyes on a single video screen. Incredible and important technology and also the first major technological advancement in the ENG in 40 years.
Some major benefits of the VNG:
· No skin preparation or electrode replacement.
· No calibration requirements.
· Clean tracings with no biological noise.
· Full four-channel, direct coupled ENG recordings (optional two-channel)
· Direct observation and video recording of patient`s eyes.
· Complete testing with eye open in a non-fixating environment.
· Observation of rotary or torsional nystagmus.
· Use of goggles for rotational testing and canalith repositionaing.
· Fast, easy recording, storage data analysis and report preperation.
· Reduced test times.
This system is distributed using a select group of "Special Instrument" dealers throughout the US. They utilize over 50 sales people and cover all 50 states.
<Click to see a screen shot of the actual system display!>
MANAGEMENT
Charles E. Phillips (President and a Director) -
Prior to forming OculoKinetics, Inc., Mr. Phillips operated Charles E. Phillips, Inc., a management and marketing consulting firm. His work has included assignments in marketing, operations and the initiation of start-up ventures. From 1974 to 1985, Mr. Phillips was Executive Vice President and Director of Akai America, Ltd., a consumer electronics company. His management background has encompassed marketing, new product planning, sales, advertising, finance, accounting, manufacturing, quality assurance and distribution. Mr. Phillips received a B.A. from Pepperdine College, Los Angeles, California with emphasis on Business and Speech Education, in 1956.
Ronald A. Waldorf (Chairman of the Board of Directors) -
Mr. Waldorf is active in overall policy formation and strategic planning for the Company. He is the inventor of the IR/Video ENG System, SafetyScope and EM/1 products. He also owns a patent covering closely related technology that has been licensed exclusively to the Company. Since 1969 Waldorf has been active in the field of otolaryngology, primarily in an academic research environment at the University of Florida, College of Medicine and at the University of California (Irvine), Department of Surgery. He has published numerous articles on vestibular and optokinetic research in international scientific and medical journals and was the principal investigator in a research grant funded by the National Institute of Health/National Institute on Alcohol Abuse and Alcoholism (NIH/NIAAA). Since 1981 he has acted as a consultant to clinics and hospitals in the Los Angeles area, including the House Ear Clinic. He has also consulted a Japanese company developing new technologies for eye movement detection. Waldorf earned an M.S. in from the Department of Physiology of the College of Medicine, University of Florida, in 1972.
Arnold D. Kay (Director) -
He has more than thirty years experience in finance, sales and administration. Mr. Kay was an employee of the Company from 1991 to 1994. He currently is co-owner and General Manager of Lomita Blueprint/CADWEST of Lomita, California, a software and computer imaging business focusing in design, graphics and distribution of CAD software and systems. Mr. Kay received a B.S. in Business Administration/Finance from California State University, Northridge, in 1961.
Barbara J. Mauch (Primary Product Development Engineer) -
She has been with the Company since 1989 and is responsible for product engineering and software development. Her background encompasses computer systems design and software development for access control of buildings and other properties. She served as a Director of the Company from 1991 to 1996. Ms. Mauch earned a B.S. in Mathematics from Northern Colorado University, in 1971 and completed the Master`s program in computer science at UCLA.
TECHNICAL ANALYSIS
Currently trading around the 35c - 40c range, EYDY is recovering off a failed break-out at 50c from a 4-month long saucer built between Nov `00 and Feb `01. The 5-month downtrend from the stocks high of 72c was also broken during the last attempt at 50c and a consolidation is appropriate before another attempt is launched. The stock is just about two-months into forming another saucer and this may be the most opportune time for accumulation. Technically, a move about the 50c range should lead to a try at the previous high and, based on company developments and a new focus on the SafetyScope product, a successful breakthrough is not unreasonable to expect. The MACD remains neutral so achieving momentum should be no problem with added exposure and interest.
CONCLUSION
With the broader markets showing a solid recovery it can also be expected that interest in the BB marketplace should return. Bargain hunters and speculators will be excited to find a gem like EYDY and with the expected surge in interest due to the SafetyScope product, EYDY is a great candidate for any speculative portfolio. The company is currently building an earnings model and we`ll be updating this report very soon with financials but until then, the story remains exciting enough to warrant establishing a position. Accumulation of the stock below 50c is highly recommended.
Pat Comer

[tlmtar]

@advisor
WKN 883610 funktioniert nicht?!

[TheAdvisorNo1]

http://www.eyedynamics.com/contactus.cfm

Besuch mal die Site, da msteht die deutsche WKN, 883610, die funktioniert auch, sonst ruf mal beim Broker an

[DieNEUE]

Nun sind wir im FOCUS der NASDAQ Tagesgewinner
YEP

http://www.bigcharts.com/markets/screener.asp?exchange=15&sc…

Die Tagesgewinner mit den hohen Umsätzen sind ein HOBBY der US Boys.
CALY ist dabei und zum Glück nicht zu stark gestiegen.
Mir sind 30% pro Tag lieber als sofort 110%
Jeden Tag 30% mal 5 Tage sind auch 150%

STRONG-LONG
Ich denke 1,5$ ist der erste ernst zu nehmende Widerstand.

Im Augenblick heißt das Motto:
Gewinne laufen lassen.

Wer hat denn nun auf mich gehört ??? -Gemäß Thread Titel ???
MfG
DN

[hausierer]

Fünf Tage hintereinander ein Plus von je 30% macht am fünften Tag ein Plus von insgesamt 272% !!!!
Und nicht 150%!!

[DieNEUE]

Sorry Das lerne ich noch
Hats einer gesehen-PEINLICH-


AUF zum VÖ...........eln.
Sorry zu den Vögeln.
Denn Calypte ist ein Kolibri

Auf die 230%
MfG
DN

[PUSHERKING]

News von CALY
Wednesday November 14, 9:38 pm Eastern Time
Press Release
SOURCE: Calypte Biomedical Corporation
Planned Parenthood Mar Monte to Offer Calypte`s Urine HIV-1 Antibody Tests
ALAMEDA, Calif.--(BW HealthWire)--Nov. 14, 2001--Calypte Biomedical Corporation (OTCBB:CALY - news) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte`s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organization, has the only CLIA-approved (Clinical Laboratory Improvement Act) laboratory in the Planned Parenthood organization.

Calypte has worked closely with Planned Parenthood in San Jose over the past several months to provide the required support for the laboratory to complete its evaluation of Calypte`s urine screening and supplemental tests for HIV-1 antibodies. The State of California has licensing requirements for all California laboratories that perform any type of HIV testing. Planned Parenthood has successfully completed requirements for licensure for Calypte`s urine HIV testing in the State of California. Planned Parenthood anticipates a very positive response to offering the option of urine HIV testing. The laboratory currently performs more than 12,000 HIV tests each year. Additionally, Planned Parenthood indicates that with the availability of testing systems for Chlamydia, Gonorrhea and HIV on urine, it can offer a comprehensive testing panel for the most common sexually transmitted diseases (STDs) on one urine specimen. Among the several Planned Parenthood clinics served by the laboratory at Planned Parenthood Mar Monte are the Planned Parenthood clinics on the Alameda and in Blossom Hill, both of which are in the San Jose area.

According to Nancy Katz, Calypte`s president & CEO, ``Planned Parenthood`s decision to offer the urine HIV test represents a milestone in Calypte`s combined objectives of marketing our non-invasive urine HIV testing technology in the health service market and participating in the fight against AIDS. I am certain that Planned Parenthood will see an increase in voluntary testing for HIV that is consistent with the CDC`s (Centers for Disease Control) initiative to increase the number of people who are aware of their HIV status through voluntary testing. Our experience with other healthcare providers that have chosen urine as an alternative to blood testing for HIV is that more people will be voluntarily tested using urine because it is simple to collect, does not require the invasive process of blood drawing and provides equivalent accuracy to blood testing when coupled with urine western blot testing. The addition of urine HIV testing as an option by Planned Parenthood is a clear indication of their commitment to their constituency.``

Planned Parenthood Mar Monte began offering urine HIV testing using Calypte`s HIV-1 urine antibody tests on Nov. 12, 2001. This relationship with Planned Parenthood Mar Monte has raised interest with other Planned Parenthood locations for urine testing for STDs. Calypte is currently working closely with another northern California Planned Parenthood group and is following up with groups in the Mid-West that have expressed interest in Calypte`s urine test for HIV.

Calypte Biomedical Corporation headquartered in Alameda is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission (``SEC``), including its annual report on Form 10-K for the year ended December 31, 2000 and its subsequent filings with the SEC.


--------------------------------------------------------------------------------
Contact:

Calypte Biomedical Corporation
Joe Whittier, 510/749-5125
www.calypte.com

[aceman]

Was soll das heissen?

[PUSHERKING]

Ein schönes Plus
Andy